Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195,388 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP. O'Farrell AM, et al. Among authors: li j, li x. Clin Ther. 2007 Aug;29(8):1692-705. doi: 10.1016/j.clinthera.2007.08.005. Clin Ther. 2007. PMID: 17919550 Clinical Trial.
Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM, de Bruijne J, O'Farrell AM, Boyea T, Li J, Bracken M, Li X, Campbell D, Guler HP, Weegink CJ, Schinkel J, Molenkamp R, van de Wetering de Rooij J, van Vliet A, Janssen HL, de Knegt RJ, Reesink HW. Hotho DM, et al. Among authors: li j, li x. Antivir Ther. 2012;17(2):365-75. doi: 10.3851/IMP1989. Epub 2011 Nov 30. Antivir Ther. 2012. PMID: 22293533 Clinical Trial.
Effect of Food on the Pharmacokinetics of Quizartinib.
Li J, Holmes M, Kankam M, Trone D, Mendell J, Gammon G. Li J, et al. Clin Pharmacol Drug Dev. 2020 Feb;9(2):277-286. doi: 10.1002/cpdd.770. Epub 2020 Jan 8. Clin Pharmacol Drug Dev. 2020. PMID: 31916418 Free PMC article. Clinical Trial.
An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.
Sanga M, James J, Marini J, Gammon G, Hale C, Li J. Sanga M, et al. Among authors: li j. Xenobiotica. 2017 Oct;47(10):856-869. doi: 10.1080/00498254.2016.1217100. Epub 2017 Jul 25. Xenobiotica. 2017. PMID: 27460866 Clinical Trial.
195,388 results
You have reached the last available page of results. Please see the User Guide for more information.